Back

Psychometric Validation of a Clinician-Reported Clinical Severity Assessment in STXBP1-Related Disorder

Abbott, M.; Angione, K.; Benke, T. A.; Chao, H.-T.; Coyne, J.; Cunningham, K.; deCampo, D.; Downs, J.; Goss, J.; Grinspan, Z.; Jolliffe, M.; Knowles, J.; Marsh, E.; McKee, J. L.; Miele, A.; Pierce, S. R.; Ruggiero, S. M.; Rigby, C. S.; Stringfellow, M.; Tefft, S.; Xiong, K.; Helbig, I.; Demarest, S.

2026-05-29 neurology
10.64898/2026.05.27.26354243 medRxiv
Show abstract

AIM: STXBP1-related disorder (STXBP1-RD) is a severe developmental and epileptic encephalopathy characterized by early-onset seizures and persistent cognitive and motor impairments. With disease-modifying trials emerging, a disorder-specific severity scale is needed. To address this, we adapted a validated clinician-reported measure from CDKL5 Deficiency Disorder to develop the STXBP1 Clinical Severity Assessment (S-CSA) and evaluated its psychometric properties. METHOD: The S-CSA was adapted from the CDKL5 Clinical Severity Assessment through expert consensus sessions with STXBP1 clinicians. Revisions addressed gaps in motor and vision domains, adding tremor and vision items. The measure was administered to 123 individuals with STXBP1-RD. Psychometric evaluation included confirmatory factor analysis, internal consistency, composite reliability, average variance extracted, and distinctiveness, compared with recommended thresholds. RESULTS: Analyses supported a three-domain structure (motor, communication, vision) with factor loadings >0.5 and strong internal consistency (Cronbachs alpha >0.7; composite reliability >0.88). Model fit and variance metrics met recommended standards, and domains demonstrated distinctiveness. No ceiling or floor effects were observed. Minimal skew was seen in motor (0.34) and communication (0.16) domains; positive skew in vision (2.2) was seen, identifying patients with and without cortical visual impairment. INTERPRETATION: The S-CSA demonstrates strong validity and reliability in STXBP1-RD and may show utility in clinical trials for STXBP1-RD and potentially other severe DEEs. Key Words: STXBP1-Related Disorder, Developmental and Epileptic Encephalopathies, Clinical Outcome Assessments

Matching journals

The top 4 journals account for 50% of the predicted probability mass.